Jan 29 (Reuters) - Biogen Inc and partner Eisai Co Ltd said on Friday the U.S. Food and Drug Administration has extended the review period by three months for aducanumab, its experimental treatment for Alzheimer’s disease. (Reporting by Manojna Maddipatla in Bengaluru; Editing by Shounak Dasgupta)
我们的标准: 汤森路透“信任原则”